Integra LifeSciences Holdings (IART) 2013年年度报告「NASDAQ」.pdf

《Integra LifeSciences Holdings (IART) 2013年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Integra LifeSciences Holdings (IART) 2013年年度报告「NASDAQ」.pdf（144页珍藏版）》请在三个皮匠报告上搜索。

1、LIMITING UNCERTAINTY IS HOW WE MAKE A DIFFERENCE.2013 Annual ReportTotal RevenuesSelected Financial Data:2013 Revenues by Geographic AreaUnited StatesEuropeRest of World2013 Revenues by SegmentSegment%of Total Revenues Key Product Areas 2013 RevenuesU.S.NeurosurgeryU.S.InstrumentsU.S.ExtremitiesU.S.

2、Spine&OtherInternational21%19%16%21%23%Dural repair,ultrasonic aspiration,cranial stabilization,stereotaxy,neuro critical careGeneral and specialty hand-held surgical instruments in the hospital and office-based se?ings;surgical headlights and retractorsSo?tissue repair for nerve,tendon,skin and wou

3、nd;fixation and joint replacement in foot,ankle,hand,wrist,elbow and shoulderMIS spine system,traditional spine fusion,orthobiologics,private label*Select product lines from each of Neurosurgery,Instruments,Extremities and Spine$172 Million$160 Million$134 Million$180 Million$190 MillionCompany at a

4、 GlanceRegion2013 Revenues$643 Million$94 Million$99 MillionOperating Cash FlowDiluted Earnings Per ShareIn 2012,we generated$59.1 million in cash flows from operations,which was reduced by a$29.8 million tax withholding payment in connection with the release of certain deferred stock units and$30.6

5、 million of accreted interest paid at the maturity of our 2012 Senior Convertible Note.*?To Our Stockholders:In 2013,despite challenges and an evolving healthcare environment,Integra made positive headway inadvancing our strategic goals of execution,optimization and accelerating growth,and ended the

6、 year on apositive note.We entered 2014 with greater stability and a stronger foundation,and are progressing towardbecoming a multi-billion dollar,global medical technology company that makes a difference in peoples livesand is a high-quality investment for our stockholders.2013 HighlightsWe had sev